Journal ArticleDOI
"Hit the primary": A paradigm shift in the treatment of metastatic prostate cancer?
TLDR
Preclinical data, clinical experience, and challenges in local treatment in de novo metastatic PC are reviewed and discussed, and modern radiation therapy can play a significant role owing to its intrinsic capability to act as a more general immune response modifier.Abstract:
Patients with metastatic prostate cancer (PC) represent a heterogeneous group with survival rates varying between 13 and 75 months. The current standard treatment in this setting is hormonal therapy, with or without docetaxel-based chemotherapy. In the era of individualized medicine, however, maximizing treatment options, especially in long-term surviving patients with limited disease burden, is of capital importance. Emerging data, mainly from retrospective surgical series, show survival benefits in men diagnosed with metastatic PC following definitive therapy for the prostate. Whether the irradiation of primary tumor in a metastatic disease might improve the therapeutic ratio in association with systemic treatments remains investigational. In this scenario, modern radiation therapy (RT) can play a significant role owing to its intrinsic capability to act as a more general immune response modifier, as well as to the potentially better toxicity profile compared to surgery. Preclinical data, clinical experience, and challenges in local treatment in de novo metastatic PC are reviewed and discussed.read more
Citations
More filters
Journal ArticleDOI
Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review.
TL;DR: A meta-analysis of articles published in PubMed, MEDLINE, EMBASE, and Cochrane library to investigate the effectiveness of local consolidative therapy (LCT) against oligometastases was conducted in this article.
Posted ContentDOI
Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review
TL;DR: LCT provides oncologic benefits in the oligometastatic setting, although such benefits were less evident in RCTs than in data from observational studies.
Journal ArticleDOI
Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey.
Giorgia Timon,Barbara Alicja Jereczek-Fossa,Sergio Fersino,Cinzia Iotti,Renzo Corvò,Stefano Maria Magrini,Filippo Alongi +6 more
TL;DR: This survey investigated the current opinion of Italian radiation oncologists regarding the non-palliative radiotherapy in ab initio oligometastatic prostate cancer (OMPC) patients and confirmed their interest in OMPC management.
Journal ArticleDOI
Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome
Giulia Riva,Giulia Riva,Giulia Marvaso,Matteo Augugliaro,Matteo Augugliaro,Dario Zerini,Cristiana Fodor,Gennaro Musi,Ottavio De Cobelli,Roberto Orecchia,Barbara Alicja Jereczek-Fossa,Barbara Alicja Jereczek-Fossa +11 more
TL;DR: Prostate RT in oligometastatic patients is safe and offers long-lasting local control and when compared to ADT alone, RT on primary seems to improve biochemical control and long-term survival; however, this hypothesis should be investigated in prospective studies.
Journal ArticleDOI
Treatment of the primary in metastatic prostate cancer.
TL;DR: This article emphasizes important aspects regarding a feasible management of mPCa, with possible impact on subsequent guidelines regarding the optimal treatment of the primary in patients diagnosed with metastatic prostate cancer.
References
More filters
Journal ArticleDOI
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
TL;DR: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma.
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
TL;DR: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Journal ArticleDOI
EAU guidelines on prostate cancer
Axel Heidenreich,Gunnar Aus,Michel Bolla,Steven Joniau,Vsevolod Matveev,Hans Schmid,F. Zattoni +6 more
TL;DR: The guidelines have been updated and level of evidence/grade of recommendation added to the text enables readers to better understand the quality of the data forming the basis of the recommendations.
Journal ArticleDOI
EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet,Joaquim Bellmunt,Michel Bolla,Erik Briers,Marcus G. Cumberbatch,Maria De Santis,Nicola Fossati,Tobias Gross,Ann Henry,Steven Joniau,Thomas B. Lam,Thomas B. Lam,Malcolm David Mason,Vsevolod Matveev,Paul C. Moldovan,Roderick C.N. van den Bergh,Thomas Van den Broeck,Henk G. van der Poel,Theo H. van der Kwast,Olivier Rouvière,Ivo G. Schoots,Thomas Wiegel,Philip Cornford +22 more
TL;DR: The 2016 EAU-STRO-IOG Prostate Cancer (PCa) Guidelines present updated information on the diagnosis, and treatment of clinically localised prostate cancer and reflect the multidisciplinary nature of PCa management.